The RESET-INSPIRE study is designed to investigate individual variability in glucose response and insulin sensitivity, a key mechanism underlying metabolic-associated steatotic liver disease (MASLD) and cardiometabolic disorders. Building on findings from Project RESET, this study aims to develop and validate a continuous glucose monitoring (CGM)-based approach for assessing insulin sensitivity.
Adults aged between 21 and 70 years (including 70 yrs old) at the time of screening
Able to speak and understand English
No past history of acute myocardial infarction (heart attack), stroke or heart failure
Able to understand and voluntarily provide written informed consent prior to any study specific procedures.
Known diagnosis of diabetes mellitus (type 1 or type 2), or use of antidiabetic medication.
Current or recent (within 3 months) use of medications known to affect glucose, including but not limited to corticosteroids.
Known history of liver disease or abnormal liver function deemed clinically significant by the investigator who is a medical doctor.
Renal impairment, defined as eGFR ≤ 60mL/min/1.73m²
Recruitment is in Singapore as follows: 1. Flyer: The flyer, which contains a QR code to our landing page and the study contact number, will be distributed at various outreach events such as the Standard Chartered Marathon Race Pack Collection. Permissions will be obtained from the event organizers (if necessary, especially for non-NUS events), before distribution of flyers. 2. Word of Mouth: We are planning to inform participants of Project RESET about this study and encourage them to inform their family and friends to participate in it. 3. Project RESET Cohort: About 5000 people have signed up for Project RESET and we can look to recruit these people for this study if they have given their consent to be contacted for other studies. 4. Expression of interest online form: There was an online Town Hall conducted for all Project RESET participants on 11th and 12th of February 2026 and Project INSPIRE was introduced there with a link and QR code to Project INSPIRE.
Cohort
Prospective
Not listed
Continuous Glucose Monitor data
The continuous Glucose Monitor measures glucose in the interstitial fluid under the skin and outputs it in units of mmol/L
Blood Glucose
Blood glucose is measured at all timepoints for the OGTT and is output in mmol/L
Insulin
Insulin in the blood is measured at all timepoints of the OGTT and output in mU/L
C-Peptide
C-Peptide levels in the blood is measured at all timepoints of the OGTT and output as ng/ml
HBA1C
Blood HBA1C measured in the fasting blood sample during the OGTT and output in percentage (%)
hs-CRP
hs-CRP measured in the fasting blood sample and output as mg/L.
ESR (Alifax)
Erythrocyte Sedimentation Rate (Blood) measures ESR (Alifax) and outputs in mm.hr
Total Cholesterol
Blood Total Cholesterol in the fasting blood sample output in mmol/L
Click on the lead sponsor to view all of their trials.
